WO1994004523A1 - Dioxacycloalkane compound with renin-inhibiting activity - Google Patents
Dioxacycloalkane compound with renin-inhibiting activity Download PDFInfo
- Publication number
- WO1994004523A1 WO1994004523A1 PCT/JP1993/001156 JP9301156W WO9404523A1 WO 1994004523 A1 WO1994004523 A1 WO 1994004523A1 JP 9301156 W JP9301156 W JP 9301156W WO 9404523 A1 WO9404523 A1 WO 9404523A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- compound
- lower alkyl
- hydrogen atom
- alkyl group
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 356
- 108090000783 Renin Proteins 0.000 title claims abstract description 30
- 102100028255 Renin Human genes 0.000 title claims abstract description 30
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 28
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 85
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 79
- 150000003839 salts Chemical class 0.000 claims abstract description 63
- 238000000034 method Methods 0.000 claims abstract description 56
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 11
- 125000003710 aryl alkyl group Chemical group 0.000 claims abstract description 5
- 238000004519 manufacturing process Methods 0.000 claims description 164
- -1 methoxy methoxy group Chemical group 0.000 claims description 101
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 98
- 239000000203 mixture Substances 0.000 claims description 55
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 42
- 239000002253 acid Substances 0.000 claims description 38
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 38
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 34
- 125000006239 protecting group Chemical group 0.000 claims description 19
- 239000002841 Lewis acid Substances 0.000 claims description 18
- 125000003277 amino group Chemical group 0.000 claims description 17
- 150000007517 lewis acids Chemical class 0.000 claims description 17
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 16
- 125000002066 L-histidyl group Chemical group [H]N1C([H])=NC(C([H])([H])[C@](C(=O)[*])([H])N([H])[H])=C1[H] 0.000 claims description 14
- 125000004432 carbon atom Chemical group C* 0.000 claims description 12
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims description 11
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 11
- 125000005843 halogen group Chemical group 0.000 claims description 9
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical group O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 claims description 7
- 125000003282 alkyl amino group Chemical group 0.000 claims description 6
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 4
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 4
- DLYUQMMRRRQYAE-UHFFFAOYSA-N tetraphosphorus decaoxide Chemical compound O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 claims description 3
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims description 2
- 238000007363 ring formation reaction Methods 0.000 claims description 2
- FVAHHPPJYLVIIC-UHFFFAOYSA-N 3,4-dimethyloxolane Chemical compound CC1COCC1C FVAHHPPJYLVIIC-UHFFFAOYSA-N 0.000 claims 1
- MVYGFAZZLWOFNN-UHFFFAOYSA-N 4,4-dimethyl-1,3-dioxolane Chemical compound CC1(C)COCO1 MVYGFAZZLWOFNN-UHFFFAOYSA-N 0.000 claims 1
- LELOWRISYMNNSU-UHFFFAOYSA-N Hydrocyanic acid Natural products N#C LELOWRISYMNNSU-UHFFFAOYSA-N 0.000 claims 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 1
- 230000005494 condensation Effects 0.000 claims 1
- 238000009833 condensation Methods 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 6
- 206010019280 Heart failures Diseases 0.000 abstract description 3
- 230000001077 hypotensive effect Effects 0.000 abstract description 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 208000001953 Hypotension Diseases 0.000 abstract 1
- 208000021822 hypotensive Diseases 0.000 abstract 1
- 230000002085 persistent effect Effects 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 238000006243 chemical reaction Methods 0.000 description 149
- 239000000243 solution Substances 0.000 description 114
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 96
- 239000002904 solvent Substances 0.000 description 71
- 230000002829 reductive effect Effects 0.000 description 60
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 56
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 55
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 51
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 46
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 45
- 229920006395 saturated elastomer Polymers 0.000 description 43
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 42
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 36
- 238000001816 cooling Methods 0.000 description 34
- 239000012044 organic layer Substances 0.000 description 33
- 239000007787 solid Substances 0.000 description 32
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 26
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 25
- 239000002585 base Substances 0.000 description 25
- 238000003756 stirring Methods 0.000 description 23
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 23
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 21
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 20
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 20
- 239000013078 crystal Substances 0.000 description 18
- 238000003379 elimination reaction Methods 0.000 description 18
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 18
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical class CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 17
- 238000006722 reduction reaction Methods 0.000 description 17
- 235000011054 acetic acid Nutrition 0.000 description 15
- 239000007864 aqueous solution Substances 0.000 description 15
- 239000003054 catalyst Substances 0.000 description 15
- 239000012230 colorless oil Substances 0.000 description 15
- 229910052757 nitrogen Inorganic materials 0.000 description 15
- 238000010898 silica gel chromatography Methods 0.000 description 15
- 238000002360 preparation method Methods 0.000 description 14
- 238000010438 heat treatment Methods 0.000 description 13
- 239000011541 reaction mixture Substances 0.000 description 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- 229910052783 alkali metal Inorganic materials 0.000 description 12
- 239000000543 intermediate Substances 0.000 description 12
- 230000009467 reduction Effects 0.000 description 12
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 12
- 150000007513 acids Chemical class 0.000 description 11
- 150000001340 alkali metals Chemical class 0.000 description 11
- 239000012043 crude product Substances 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 10
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 10
- WTEOIRVLGSZEPR-UHFFFAOYSA-N boron trifluoride Chemical compound FB(F)F WTEOIRVLGSZEPR-UHFFFAOYSA-N 0.000 description 10
- 238000001953 recrystallisation Methods 0.000 description 10
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 9
- 150000002148 esters Chemical class 0.000 description 9
- 150000004679 hydroxides Chemical class 0.000 description 9
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 8
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 8
- 150000001342 alkaline earth metals Chemical class 0.000 description 8
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 8
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 8
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 8
- 239000000706 filtrate Substances 0.000 description 8
- 230000007062 hydrolysis Effects 0.000 description 8
- 238000006460 hydrolysis reaction Methods 0.000 description 8
- AMXOYNBUYSYVKV-UHFFFAOYSA-M lithium bromide Chemical compound [Li+].[Br-] AMXOYNBUYSYVKV-UHFFFAOYSA-M 0.000 description 8
- 239000003921 oil Substances 0.000 description 8
- ZDYVRSLAEXCVBX-UHFFFAOYSA-N pyridinium p-toluenesulfonate Chemical compound C1=CC=[NH+]C=C1.CC1=CC=C(S([O-])(=O)=O)C=C1 ZDYVRSLAEXCVBX-UHFFFAOYSA-N 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 8
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 7
- 229940024606 amino acid Drugs 0.000 description 7
- 230000003276 anti-hypertensive effect Effects 0.000 description 7
- 238000010531 catalytic reduction reaction Methods 0.000 description 7
- 239000003638 chemical reducing agent Substances 0.000 description 7
- 238000001914 filtration Methods 0.000 description 7
- 238000005755 formation reaction Methods 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 239000011734 sodium Substances 0.000 description 7
- 101800000734 Angiotensin-1 Proteins 0.000 description 6
- 102400000344 Angiotensin-1 Human genes 0.000 description 6
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 6
- ZTQSAGDEMFDKMZ-UHFFFAOYSA-N Butyraldehyde Chemical compound CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 6
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 6
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 6
- 230000002411 adverse Effects 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 6
- 238000010511 deprotection reaction Methods 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 229910052751 metal Inorganic materials 0.000 description 6
- 239000002184 metal Substances 0.000 description 6
- 239000012046 mixed solvent Substances 0.000 description 6
- 150000007524 organic acids Chemical class 0.000 description 6
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 6
- 150000004714 phosphonium salts Chemical class 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 239000012312 sodium hydride Substances 0.000 description 6
- 229910000104 sodium hydride Inorganic materials 0.000 description 6
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 6
- 229910015900 BF3 Inorganic materials 0.000 description 5
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000008030 elimination Effects 0.000 description 5
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 5
- 125000001841 imino group Chemical group [H]N=* 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- 229910052987 metal hydride Inorganic materials 0.000 description 5
- 150000004681 metal hydrides Chemical class 0.000 description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
- 150000007522 mineralic acids Chemical class 0.000 description 5
- 239000011259 mixed solution Substances 0.000 description 5
- 235000005985 organic acids Nutrition 0.000 description 5
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- YOWQWFMSQCOSBA-UHFFFAOYSA-N 2-methoxypropene Chemical compound COC(C)=C YOWQWFMSQCOSBA-UHFFFAOYSA-N 0.000 description 4
- BNDRWEVUODOUDW-UHFFFAOYSA-N 3-Hydroxy-3-methylbutan-2-one Chemical compound CC(=O)C(C)(C)O BNDRWEVUODOUDW-UHFFFAOYSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 206010020772 Hypertension Diseases 0.000 description 4
- 235000003332 Ilex aquifolium Nutrition 0.000 description 4
- 241000209027 Ilex aquifolium Species 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 4
- 229910021627 Tin(IV) chloride Inorganic materials 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 4
- FPRSPUHXEPWUBZ-HNNXBMFYSA-N benzyl (2s)-2-amino-3-phenylpropanoate Chemical compound C([C@H](N)C(=O)OCC=1C=CC=CC=1)C1=CC=CC=C1 FPRSPUHXEPWUBZ-HNNXBMFYSA-N 0.000 description 4
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 4
- NKDDWNXOKDWJAK-UHFFFAOYSA-N dimethoxymethane Chemical compound COCOC NKDDWNXOKDWJAK-UHFFFAOYSA-N 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 4
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 125000000160 oxazolidinyl group Chemical group 0.000 description 4
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 4
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 4
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 4
- NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 4
- 229910000105 potassium hydride Inorganic materials 0.000 description 4
- 235000019260 propionic acid Nutrition 0.000 description 4
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 239000012279 sodium borohydride Substances 0.000 description 4
- 229910000033 sodium borohydride Inorganic materials 0.000 description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- HPGGPRDJHPYFRM-UHFFFAOYSA-J tin(iv) chloride Chemical compound Cl[Sn](Cl)(Cl)Cl HPGGPRDJHPYFRM-UHFFFAOYSA-J 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical class CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 4
- HEVMDQBCAHEHDY-UHFFFAOYSA-N (Dimethoxymethyl)benzene Chemical compound COC(OC)C1=CC=CC=C1 HEVMDQBCAHEHDY-UHFFFAOYSA-N 0.000 description 3
- XPIJMQVLTXAGME-UHFFFAOYSA-N 1,1-dimethoxycyclohexane Chemical compound COC1(OC)CCCCC1 XPIJMQVLTXAGME-UHFFFAOYSA-N 0.000 description 3
- MEKOFIRRDATTAG-UHFFFAOYSA-N 2,2,5,8-tetramethyl-3,4-dihydrochromen-6-ol Chemical compound C1CC(C)(C)OC2=C1C(C)=C(O)C=C2C MEKOFIRRDATTAG-UHFFFAOYSA-N 0.000 description 3
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical class CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 3
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 101100272976 Panax ginseng CYP716A53v2 gene Proteins 0.000 description 3
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 3
- 238000013375 chromatographic separation Methods 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 3
- NGAZZOYFWWSOGK-UHFFFAOYSA-N ethyl-n-butyl-ketone Natural products CCCCC(=O)CC NGAZZOYFWWSOGK-UHFFFAOYSA-N 0.000 description 3
- 229910052742 iron Inorganic materials 0.000 description 3
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 241001515942 marmosets Species 0.000 description 3
- 150000002739 metals Chemical class 0.000 description 3
- 239000012285 osmium tetroxide Substances 0.000 description 3
- 229910000489 osmium tetroxide Inorganic materials 0.000 description 3
- 235000021317 phosphate Nutrition 0.000 description 3
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 3
- 235000015598 salt intake Nutrition 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 235000015424 sodium Nutrition 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- HGBOYTHUEUWSSQ-UHFFFAOYSA-N valeric aldehyde Natural products CCCCC=O HGBOYTHUEUWSSQ-UHFFFAOYSA-N 0.000 description 3
- 229910052725 zinc Inorganic materials 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 2
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 2
- PJUPKRYGDFTMTM-UHFFFAOYSA-N 1-hydroxybenzotriazole;hydrate Chemical compound O.C1=CC=C2N(O)N=NC2=C1 PJUPKRYGDFTMTM-UHFFFAOYSA-N 0.000 description 2
- HEWZVZIVELJPQZ-UHFFFAOYSA-N 2,2-dimethoxypropane Chemical compound COC(C)(C)OC HEWZVZIVELJPQZ-UHFFFAOYSA-N 0.000 description 2
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 102000004881 Angiotensinogen Human genes 0.000 description 2
- 108090001067 Angiotensinogen Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 101100274581 Caenorhabditis elegans chc-1 gene Proteins 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical class C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 2
- HCUARRIEZVDMPT-UHFFFAOYSA-N Indole-2-carboxylic acid Chemical compound C1=CC=C2NC(C(=O)O)=CC2=C1 HCUARRIEZVDMPT-UHFFFAOYSA-N 0.000 description 2
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 2
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 2
- LFTLOKWAGJYHHR-UHFFFAOYSA-N N-methylmorpholine N-oxide Chemical compound CN1(=O)CCOCC1 LFTLOKWAGJYHHR-UHFFFAOYSA-N 0.000 description 2
- WYNCHZVNFNFDNH-UHFFFAOYSA-N Oxazolidine Chemical group C1COCN1 WYNCHZVNFNFDNH-UHFFFAOYSA-N 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 2
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 2
- 229920000388 Polyphosphate Polymers 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- QQONPFPTGQHPMA-UHFFFAOYSA-N Propene Chemical compound CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 150000008065 acid anhydrides Chemical class 0.000 description 2
- 150000001336 alkenes Chemical group 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 239000000010 aprotic solvent Substances 0.000 description 2
- 125000005098 aryl alkoxy carbonyl group Chemical group 0.000 description 2
- 150000001540 azides Chemical group 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- FLLNLJJKHKZKMB-UHFFFAOYSA-N boron;tetramethylazanium Chemical compound [B].C[N+](C)(C)C FLLNLJJKHKZKMB-UHFFFAOYSA-N 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- 159000000007 calcium salts Chemical class 0.000 description 2
- 229950005499 carbon tetrachloride Drugs 0.000 description 2
- LADPCMZCENPFGV-UHFFFAOYSA-N chloromethoxymethylbenzene Chemical compound ClCOCC1=CC=CC=C1 LADPCMZCENPFGV-UHFFFAOYSA-N 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- FJBFPHVGVWTDIP-UHFFFAOYSA-N dibromomethane Chemical compound BrCBr FJBFPHVGVWTDIP-UHFFFAOYSA-N 0.000 description 2
- HCUYBXPSSCRKRF-UHFFFAOYSA-N diphosgene Chemical compound ClC(=O)OC(Cl)(Cl)Cl HCUYBXPSSCRKRF-UHFFFAOYSA-N 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine hydrate Chemical compound O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 2
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 2
- 229910000040 hydrogen fluoride Inorganic materials 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 125000000654 isopropylidene group Chemical group C(C)(C)=* 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 159000000003 magnesium salts Chemical class 0.000 description 2
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 2
- 239000002808 molecular sieve Substances 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 150000002894 organic compounds Chemical class 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 238000007248 oxidative elimination reaction Methods 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229960005190 phenylalanine Drugs 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 150000003016 phosphoric acids Chemical class 0.000 description 2
- 239000001205 polyphosphate Substances 0.000 description 2
- 235000011176 polyphosphates Nutrition 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 238000012746 preparative thin layer chromatography Methods 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 2
- AOJFQRQNPXYVLM-UHFFFAOYSA-N pyridin-1-ium;chloride Chemical compound [Cl-].C1=CC=[NH+]C=C1 AOJFQRQNPXYVLM-UHFFFAOYSA-N 0.000 description 2
- 150000003222 pyridines Chemical class 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 238000007142 ring opening reaction Methods 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 2
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 230000000707 stereoselective effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 229940095064 tartrate Drugs 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 150000007970 thio esters Chemical class 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 description 2
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 2
- 239000005051 trimethylchlorosilane Substances 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- VAYGOYWDAKJOLI-USWWRNFRSA-N (2r,4s,5s)-5-amino-6-cyclohexylhexane-2,4-diol Chemical class C[C@@H](O)C[C@H](O)[C@@H](N)CC1CCCCC1 VAYGOYWDAKJOLI-USWWRNFRSA-N 0.000 description 1
- HIQSHBQGIXVMBC-YFKPBYRVSA-N (2s)-2-amino-3-(1h-imidazol-5-yl)propanehydrazide Chemical compound NNC(=O)[C@@H](N)CC1=CN=CN1 HIQSHBQGIXVMBC-YFKPBYRVSA-N 0.000 description 1
- VRFKAMBVWYQNIC-IHRRRGAJSA-N (2s,4s,5s)-5-amino-6-cyclohexyl-1-(methoxymethoxy)hexane-2,4-diol Chemical class COCOC[C@@H](O)C[C@H](O)[C@@H](N)CC1CCCCC1 VRFKAMBVWYQNIC-IHRRRGAJSA-N 0.000 description 1
- VAYGOYWDAKJOLI-DLOVCJGASA-N (2s,4s,5s)-5-amino-6-cyclohexylhexane-2,4-diol Chemical class C[C@H](O)C[C@H](O)[C@@H](N)CC1CCCCC1 VAYGOYWDAKJOLI-DLOVCJGASA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- PAAZPARNPHGIKF-UHFFFAOYSA-N 1,2-dibromoethane Chemical compound BrCCBr PAAZPARNPHGIKF-UHFFFAOYSA-N 0.000 description 1
- MASDFXZJIDNRTR-UHFFFAOYSA-N 1,3-bis(trimethylsilyl)urea Chemical compound C[Si](C)(C)NC(=O)N[Si](C)(C)C MASDFXZJIDNRTR-UHFFFAOYSA-N 0.000 description 1
- SGUVLZREKBPKCE-UHFFFAOYSA-N 1,5-diazabicyclo[4.3.0]-non-5-ene Chemical compound C1CCN=C2CCCN21 SGUVLZREKBPKCE-UHFFFAOYSA-N 0.000 description 1
- OHVLMTFVQDZYHP-UHFFFAOYSA-N 1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-2-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound N1N=NC=2CN(CCC=21)C(CN1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)=O OHVLMTFVQDZYHP-UHFFFAOYSA-N 0.000 description 1
- YIWGJFPJRAEKMK-UHFFFAOYSA-N 1-(2H-benzotriazol-5-yl)-3-methyl-8-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carbonyl]-1,3,8-triazaspiro[4.5]decane-2,4-dione Chemical compound CN1C(=O)N(c2ccc3n[nH]nc3c2)C2(CCN(CC2)C(=O)c2cnc(NCc3cccc(OC(F)(F)F)c3)nc2)C1=O YIWGJFPJRAEKMK-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- OSUKSSHOHKZSJC-UHFFFAOYSA-N 12591-02-5 Chemical compound ClP(=O)=O OSUKSSHOHKZSJC-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- GRCYEAFJPWXUQL-UHFFFAOYSA-N 2,2,3-trimethyl-1,3-oxazolidine Chemical compound CN1CCOC1(C)C GRCYEAFJPWXUQL-UHFFFAOYSA-N 0.000 description 1
- LKXGAIPPBQYEJB-UHFFFAOYSA-N 2,2,4,4-tetramethyl-1,3-dioxolane Chemical compound CC1(C)COC(C)(C)O1 LKXGAIPPBQYEJB-UHFFFAOYSA-N 0.000 description 1
- OXQHJIGWZNIQDS-UHFFFAOYSA-N 2,2-dimethoxybutane Chemical compound CCC(C)(OC)OC OXQHJIGWZNIQDS-UHFFFAOYSA-N 0.000 description 1
- VSHIRTNKIXRXMI-UHFFFAOYSA-N 2,2-dimethyl-1,3-oxazolidine Chemical compound CC1(C)NCCO1 VSHIRTNKIXRXMI-UHFFFAOYSA-N 0.000 description 1
- YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 description 1
- ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 2,3-dimethylbutane Chemical group CC(C)C(C)C ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 0.000 description 1
- LZIPBJBQQPZLOR-UHFFFAOYSA-N 2-(4-methylphenyl)sulfonyloxyethyl 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OCCOS(=O)(=O)C1=CC=C(C)C=C1 LZIPBJBQQPZLOR-UHFFFAOYSA-N 0.000 description 1
- OXQGTIUCKGYOAA-UHFFFAOYSA-N 2-Ethylbutanoic acid Chemical compound CCC(CC)C(O)=O OXQGTIUCKGYOAA-UHFFFAOYSA-N 0.000 description 1
- WZFUQSJFWNHZHM-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 WZFUQSJFWNHZHM-UHFFFAOYSA-N 0.000 description 1
- IHCCLXNEEPMSIO-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperidin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 IHCCLXNEEPMSIO-UHFFFAOYSA-N 0.000 description 1
- CFMZSMGAMPBRBE-UHFFFAOYSA-N 2-hydroxyisoindole-1,3-dione Chemical compound C1=CC=C2C(=O)N(O)C(=O)C2=C1 CFMZSMGAMPBRBE-UHFFFAOYSA-N 0.000 description 1
- LXBGSDVWAMZHDD-UHFFFAOYSA-N 2-methyl-1h-imidazole Chemical compound CC1=NC=CN1 LXBGSDVWAMZHDD-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
- 125000003229 2-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000005916 2-methylpentyl group Chemical group 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- VWIIJDNADIEEDB-UHFFFAOYSA-N 3-methyl-1,3-oxazolidin-2-one Chemical compound CN1CCOC1=O VWIIJDNADIEEDB-UHFFFAOYSA-N 0.000 description 1
- YGHRJJRRZDOVPD-UHFFFAOYSA-N 3-methylbutanal Chemical compound CC(C)CC=O YGHRJJRRZDOVPD-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 102000005862 Angiotensin II Human genes 0.000 description 1
- 101800000733 Angiotensin-2 Proteins 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 229910001369 Brass Inorganic materials 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- XJUZRXYOEPSWMB-UHFFFAOYSA-N Chloromethyl methyl ether Chemical compound COCCl XJUZRXYOEPSWMB-UHFFFAOYSA-N 0.000 description 1
- YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 description 1
- HDFFVHSMHLDSLO-UHFFFAOYSA-N Dibenzyl phosphate Chemical compound C=1C=CC=CC=1COP(=O)(O)OCC1=CC=CC=C1 HDFFVHSMHLDSLO-UHFFFAOYSA-N 0.000 description 1
- ASMQGLCHMVWBQR-UHFFFAOYSA-N Diphenyl phosphate Chemical compound C=1C=CC=CC=1OP(=O)(O)OC1=CC=CC=C1 ASMQGLCHMVWBQR-UHFFFAOYSA-N 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- BXRMEWOQUXOLDH-LURJTMIESA-N L-Histidine methyl ester Chemical compound COC(=O)[C@@H](N)CC1=CN=CN1 BXRMEWOQUXOLDH-LURJTMIESA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 125000003440 L-leucyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C(C([H])([H])[H])([H])C([H])([H])[H] 0.000 description 1
- 125000003416 L-methionyl group Chemical group [H]N([H])[C@]([H])(C(*)=O)C([H])([H])C([H])([H])SC([H])([H])[H] 0.000 description 1
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 1
- 125000003580 L-valyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(C([H])([H])[H])(C([H])([H])[H])[H] 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 239000012448 Lithium borohydride Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 1
- VCUFZILGIRCDQQ-KRWDZBQOSA-N N-[[(5S)-2-oxo-3-(2-oxo-3H-1,3-benzoxazol-6-yl)-1,3-oxazolidin-5-yl]methyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C1O[C@H](CN1C1=CC2=C(NC(O2)=O)C=C1)CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F VCUFZILGIRCDQQ-KRWDZBQOSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-N Nitrous acid Chemical compound ON=O IOVCWXUNBOPUCH-UHFFFAOYSA-N 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 101150064053 Rffl gene Proteins 0.000 description 1
- 239000002262 Schiff base Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- 238000007239 Wittig reaction Methods 0.000 description 1
- JAWMENYCRQKKJY-UHFFFAOYSA-N [3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-ylmethyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-en-8-yl]-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]methanone Chemical compound N1N=NC=2CN(CCC=21)CC1=NOC2(C1)CCN(CC2)C(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F JAWMENYCRQKKJY-UHFFFAOYSA-N 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- YBCVMFKXIKNREZ-UHFFFAOYSA-N acoh acetic acid Chemical compound CC(O)=O.CC(O)=O YBCVMFKXIKNREZ-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 125000001980 alanyl group Chemical group 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 229960002478 aldosterone Drugs 0.000 description 1
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N aldosterone group Chemical group [C@@H]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@]12C=O)C(=O)CO PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 1
- 150000007933 aliphatic carboxylic acids Chemical class 0.000 description 1
- 150000005325 alkali earth metal hydroxides Chemical class 0.000 description 1
- 229910000272 alkali metal oxide Inorganic materials 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 230000001195 anabolic effect Effects 0.000 description 1
- 229950006323 angiotensin ii Drugs 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 1
- 125000001942 asparaginyl group Chemical group 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- XTKDAFGWCDAMPY-UHFFFAOYSA-N azaperone Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCN(C=2N=CC=CC=2)CC1 XTKDAFGWCDAMPY-UHFFFAOYSA-N 0.000 description 1
- RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 description 1
- 229910001863 barium hydroxide Inorganic materials 0.000 description 1
- ZUDYPQRUOYEARG-UHFFFAOYSA-L barium(2+);dihydroxide;octahydrate Chemical compound O.O.O.O.O.O.O.O.[OH-].[OH-].[Ba+2] ZUDYPQRUOYEARG-UHFFFAOYSA-L 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical class C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 239000012964 benzotriazole Substances 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- XFULYMQQCZRWQB-HNNXBMFYSA-N benzyl (2s)-2-hydroxy-3-phenylpropanoate Chemical compound C([C@H](O)C(=O)OCC=1C=CC=CC=1)C1=CC=CC=C1 XFULYMQQCZRWQB-HNNXBMFYSA-N 0.000 description 1
- XSIOKAXOPJZPIG-ZDUSSCGKSA-N benzyl n-[(2s)-1-cyclohexyl-1-oxopropan-2-yl]carbamate Chemical compound N([C@@H](C)C(=O)C1CCCCC1)C(=O)OCC1=CC=CC=C1 XSIOKAXOPJZPIG-ZDUSSCGKSA-N 0.000 description 1
- RXUBZLMIGSAPEJ-UHFFFAOYSA-N benzyl n-aminocarbamate Chemical compound NNC(=O)OCC1=CC=CC=C1 RXUBZLMIGSAPEJ-UHFFFAOYSA-N 0.000 description 1
- 125000000649 benzylidene group Chemical group [H]C(=[*])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- SIOVKLKJSOKLIF-UHFFFAOYSA-N bis(trimethylsilyl)acetamide Chemical compound C[Si](C)(C)OC(C)=N[Si](C)(C)C SIOVKLKJSOKLIF-UHFFFAOYSA-N 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000010951 brass Substances 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- AIXAANGOTKPUOY-UHFFFAOYSA-N carbachol Chemical group [Cl-].C[N+](C)(C)CCOC(N)=O AIXAANGOTKPUOY-UHFFFAOYSA-N 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 150000001728 carbonyl compounds Chemical class 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 229940061627 chloromethyl methyl ether Drugs 0.000 description 1
- QQVDYSUDFZZPSU-UHFFFAOYSA-M chloromethylidene(dimethyl)azanium;chloride Chemical compound [Cl-].C[N+](C)=CCl QQVDYSUDFZZPSU-UHFFFAOYSA-M 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 239000004020 conductor Substances 0.000 description 1
- 150000005676 cyclic carbonates Chemical class 0.000 description 1
- RVOJTCZRIKWHDX-UHFFFAOYSA-N cyclohexanecarbonyl chloride Chemical compound ClC(=O)C1CCCCC1 RVOJTCZRIKWHDX-UHFFFAOYSA-N 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- 125000003963 dichloro group Chemical group Cl* 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 150000002081 enamines Chemical class 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- WMYNMYVRWWCRPS-UHFFFAOYSA-N ethynoxyethane Chemical group CCOC#C WMYNMYVRWWCRPS-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000010265 fast atom bombardment Methods 0.000 description 1
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- JEGUKCSWCFPDGT-UHFFFAOYSA-N h2o hydrate Chemical compound O.O JEGUKCSWCFPDGT-UHFFFAOYSA-N 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- KGJDENUFWDGCFF-UHFFFAOYSA-N hex-5-enylcyclohexane Chemical compound C=CCCCCC1CCCCC1 KGJDENUFWDGCFF-UHFFFAOYSA-N 0.000 description 1
- TXGJTWACJNYNOJ-UHFFFAOYSA-N hexane-2,4-diol Chemical compound CCC(O)CC(C)O TXGJTWACJNYNOJ-UHFFFAOYSA-N 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 150000002429 hydrazines Chemical class 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 150000003949 imides Chemical class 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 229910003480 inorganic solid Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- OWFXIOWLTKNBAP-UHFFFAOYSA-N isoamyl nitrite Chemical compound CC(C)CCON=O OWFXIOWLTKNBAP-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- FMKOJHQHASLBPH-UHFFFAOYSA-N isopropyl iodide Chemical compound CC(C)I FMKOJHQHASLBPH-UHFFFAOYSA-N 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 125000001998 leucyl group Chemical group 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 235000014659 low sodium diet Nutrition 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 125000001288 lysyl group Chemical group 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- COTNUBDHGSIOTA-UHFFFAOYSA-N meoh methanol Chemical compound OC.OC COTNUBDHGSIOTA-UHFFFAOYSA-N 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000002073 methionyl group Chemical group 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- BHLAPZWOGGWVRR-ZETCQYMHSA-N methyl (2s)-3-(1h-imidazol-5-yl)-2-(methylamino)propanoate Chemical compound COC(=O)[C@@H](NC)CC1=CN=CN1 BHLAPZWOGGWVRR-ZETCQYMHSA-N 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- VMESOKCXSYNAKD-UHFFFAOYSA-N n,n-dimethylhydroxylamine Chemical compound CN(C)O VMESOKCXSYNAKD-UHFFFAOYSA-N 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- LWFWUJCJKPUZLV-UHFFFAOYSA-N n-trimethylsilylacetamide Chemical compound CC(=O)N[Si](C)(C)C LWFWUJCJKPUZLV-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N ornithyl group Chemical group N[C@@H](CCCN)C(=O)O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- 150000002917 oxazolidines Chemical group 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 description 1
- 125000006503 p-nitrobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1[N+]([O-])=O)C([H])([H])* 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 229910003445 palladium oxide Inorganic materials 0.000 description 1
- JQPTYAILLJKUCY-UHFFFAOYSA-N palladium(ii) oxide Chemical compound [O-2].[Pd+2] JQPTYAILLJKUCY-UHFFFAOYSA-N 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- CMPQUABWPXYYSH-UHFFFAOYSA-N phenyl phosphate Chemical compound OP(O)(=O)OC1=CC=CC=C1 CMPQUABWPXYYSH-UHFFFAOYSA-N 0.000 description 1
- 125000000405 phenylalanyl group Chemical group 0.000 description 1
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- OJMIONKXNSYLSR-UHFFFAOYSA-N phosphorous acid Chemical compound OP(O)O OJMIONKXNSYLSR-UHFFFAOYSA-N 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- FAIAAWCVCHQXDN-UHFFFAOYSA-N phosphorus trichloride Chemical compound ClP(Cl)Cl FAIAAWCVCHQXDN-UHFFFAOYSA-N 0.000 description 1
- 125000000612 phthaloyl group Chemical group C(C=1C(C(=O)*)=CC=CC1)(=O)* 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- BIFDXOOJPDHKJH-UHFFFAOYSA-N piperidine-1-carbonyl chloride Chemical compound ClC(=O)N1CCCCC1 BIFDXOOJPDHKJH-UHFFFAOYSA-N 0.000 description 1
- 125000005936 piperidyl group Chemical group 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229910003446 platinum oxide Inorganic materials 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 239000012286 potassium permanganate Substances 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- IVRIRQXJSNCSPQ-UHFFFAOYSA-N propan-2-yl carbonochloridate Chemical compound CC(C)OC(Cl)=O IVRIRQXJSNCSPQ-UHFFFAOYSA-N 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000011403 purification operation Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 239000002461 renin inhibitor Substances 0.000 description 1
- 230000036454 renin-angiotensin system Effects 0.000 description 1
- 229940086526 renin-inhibitors Drugs 0.000 description 1
- 238000001226 reprecipitation Methods 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000002072 seryl group Chemical group 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 229960002317 succinimide Drugs 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 150000003573 thiols Chemical group 0.000 description 1
- 125000001239 threonyl group Chemical group 0.000 description 1
- 239000011135 tin Substances 0.000 description 1
- 229910052718 tin Inorganic materials 0.000 description 1
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 125000005270 trialkylamine group Chemical group 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- 125000006000 trichloroethyl group Chemical group 0.000 description 1
- SYQIIBRVOSBWME-UHFFFAOYSA-N trichloromethyl formate Chemical compound ClC(Cl)(Cl)OC=O SYQIIBRVOSBWME-UHFFFAOYSA-N 0.000 description 1
- IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- MCULRUJILOGHCJ-UHFFFAOYSA-N triisobutylaluminium Chemical compound CC(C)C[Al](CC(C)C)CC(C)C MCULRUJILOGHCJ-UHFFFAOYSA-N 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000002233 tyrosyl group Chemical group 0.000 description 1
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002114 valyl group Chemical group 0.000 description 1
- 229920001567 vinyl ester resin Polymers 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
- C07D295/205—Radicals derived from carbonic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C233/63—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/16—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/18—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by doubly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
- C07C275/20—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
- C07C275/24—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
- C07D295/215—Radicals derived from nitrogen analogues of carbonic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
- C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D317/28—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Definitions
- Dioxacycloalkane compounds having renin inhibitory activity having renin inhibitory activity
- the present invention relates to a novel dioxacycloalkane compound having renin inhibitory activity, and is used in the field of medicine as a therapeutic agent for hypertension and the like.
- the renin-angiotensin system is one of the blood pressure-increasing systems in vivo, and is an important regulator of blood pressure and body fluid electrolytes.
- Renin is a proteolytic enzyme consisting of amino acids 340, which specifically degrades angiotensinogen in plasma. It acts on and cleaves angiotensinogen in plasma, and is composed of 10 amino acid residues. Resulting in angiotensin I (AI). AI is further cleaved by angiotensin-converting enzyme (ACE), resulting in angiotensin II (AID) consisting of eight amino acid residues. All has a strong pressor action, and renin is the rate-limiting enzyme in this system.
- ACE angiotensin-converting enzyme
- AID angiotensin II
- renin inhibitors are useful as remedies for hypertension due to renin excess and as anabolic drugs for identifying patients with hypertension due to renin excess, and various studies have been conducted in recent years.
- peptide compounds having renin inhibitory activity there have been mentioned W0990 / 07521, JP-A-64-19071, and JP-A-11-122. No. 2 1 3 5 7; Japanese Unexamined Patent Publication No. Many reports have been reported, such as Japanese Patent Application Publication No. 4-150382.
- peptide derivatives having a known renin inhibitory activity could not sufficiently exert their pharmacological effects by oral administration.
- An object of the present invention is to provide a novel compound having an excellent renin inhibitory action and capable of being orally administered.
- the present inventors have conducted intensive studies in order to solve the above-mentioned problems, and as a result, the C-terminal
- R 4 and R 5, a and E are the same or different and each represents a hydrogen atom or a lower alkyl group - C (R 29) (R 30) one or one CH 2 CH 2 one (R 29 and R 3 ° May be the same or different and may be a hydrogen atom, a lower alkyl group, a phenyl group or R 29 and R 3G may be combined to form a ring having 5 to 7 carbon atoms.
- the present invention is as follows.
- R ie , R 11 and R 12 may be the same or different and represent a hydrogen atom, a lower alkyl group, a halogen atom, an amino group, a lower alkylamino group, a lower dialkylamino group or — 0—R 15
- R 15 is a hydrogen atom, a lower alkyl group, a lower alkanol group or an amino acid acyl group
- n and n are each independently 0-5, and their sum is an integer of 1-5;
- Q 1 is one CH 5 — 0—, -S-, -so- S0 2 —
- R 16 and R 17 are the same or different and are a lower alkyl group or a halogen atom
- R 18 is a hydrogen atom or a lower alkyl group
- R 1S and R 2e are a lower alkyl group or
- R 21 and R 22 are a hydrogen atom or a lower alkyl group), and P and q are each independently 1 to 4, and their sum is an integer not exceeding 5. ) Is;
- R 13 is a hydrogen atom or a lower alkyl group, and R 23 is a hydrogen atom or a lower alkyl group);
- R 14 is a hydrogen atom, an amino group, a lower alkylamino group, a lower dialkylamino group, a hydroxyl group, a lower alkoxy group, a methoxymethoxy group, a methoxy ethoxy methoxy group Or
- Q 6 is the same as Q 5
- Q 7 is the same as Q 4
- Q 8 is —CH 2 — or one NR 24 —
- R 24 is a hydrogen atom or a lower alkyl group
- a and b are each independently 1 to 4, and the sum thereof is an integer not exceeding 5.), or a lower alkyl group which may be substituted with a group represented by A benzyl group which may be substituted);
- X is, - CO- or -S0 2 - and is;
- Y is —CH 2 —, 10 — or —NR 25 — (R 25 is a hydrogen atom or a lower alkyl group);
- R 1 is an aralkyl group optionally substituted with a lower alkoxy group
- R 6 , R 7 .. R 8 and R 9 are the same or different and are a hydrogen atom, a halogen atom, a hydroxyl group or a lower alkoxy group;
- R 2 is a hydrogen atom or a lower alkyl group
- R 3 is — (CH 2 ) d one SR 26 (d is an integer of 1 to 5, R 26 is a hydrogen atom or a lower alkyl group), a lower alkyl group,
- R 27 is a hydrogen atom, a lower alkyl group or a CH 20 —CO—R 28 (R 28 is a lower alkyl group or a lower alkoxy group));
- R 4 and R 5 are the same or different and are a hydrogen atom or a lower alkyl group
- E is —C (R 29 ) (R 30 ) or —CH 2 CH 2 (R 29 and R 3fl are the same or different and are a hydrogen atom, a lower alkyl group, a phenyl group or R 29 and R 3fl together May form a ring having 5 to 7 carbon atoms).
- R 29 and R 3fl are the same or different and are a hydrogen atom, a lower alkyl group, a phenyl group or R 29 and R 3fl together May form a ring having 5 to 7 carbon atoms).
- R 31 is a hydrogen atom or a lower alkyl group
- R 32 is a hydrogen atom or a lower alkyl group
- R 33 and R 34 are the same or different and are a hydrogen atom or a lower alkyl group; Which is an integer of ⁇ 6);
- ⁇ 1 is one CH 2 —, one 0— or —NH—;
- R 2 , R 4 , R 5 , R 29 and R 3e are the same as those in the above (1)] or the dioxacycloalkane compound of the above (1) or a pharmaceutically acceptable salt thereof.
- the dioxacycloalkane compound of the above (1) which is selected from 1,3-dioxolane, or a pharmaceutically acceptable salt thereof.
- a renin-inhibiting composition comprising a pharmaceutically suitable carrier and a renin-inhibiting effective amount of the dioxacycloalkane compound of (1) or a pharmaceutically acceptable salt thereof. object.
- a renin-inhibiting composition comprising a pharmaceutically suitable carrier and a renin-inhibiting effective amount of the dioxacycloalkane compound of (2) or a pharmaceutically acceptable salt thereof.
- a renin-inhibiting composition comprising a pharmaceutically suitable carrier and a renin-inhibiting effective amount of the dioxacycloalkane compound of (3) or a pharmaceutically acceptable salt thereof.
- Z 1 is a hydrogen atom or an N-protecting group
- Z 2 is a hydrogen atom or a hydroxyl-protecting group
- Z 3 is an oxazolidinine ring which may be substituted together with a hydrogen atom or Z 2
- R 4 and R 5 may be the same or different and each is a hydrogen atom or a lower alkyl group).
- R 35 is a lower alkyl group; R 4 and R 5 are the same or different and are a hydrogen atom or a lower alkyl group) in the presence of a Lewis acid
- R 3S is a lower alkyl group
- R 4 and R 5 are the same or different and are a hydrogen atom or a lower alkyl group
- Z 6 is a hydroxyl-protecting group.
- Z 3 , R 4 and R 5 are the same as in the above (7);
- Z 5 is water Which is a hydrogen atom or a hydroxyl protecting group
- Z 1, Z 2, Z 3, R 4 and R 5 are as defined above (7); E one C (R 29) (R 30 ) - or -CH 2 CH 2 - (R 29 and R 3 are the same or different and each may be a hydrogen atom, a lower alkyl group, a phenyl group, or R 2S and R 3fl may be taken together to form a ring having 5 to 7 carbon atoms).
- E one C (R 29) (R 30 ) - or -CH 2 CH 2 - R 29 and R 3 are the same or different and each may be a hydrogen atom, a lower alkyl group, a phenyl group, or R 2S and R 3fl may be taken together to form a ring having 5 to 7 carbon atoms).
- R 4 and R 5 are the same or different and are a hydrogen atom or a lower alkyl group; R 36 is a lower alkyl group or a benzyl group; and Z 6 is a hydroxyl protecting group).
- Asetaru an acid including Lewis acid compound represented by the catalyst; (Zeta 5 is a hydrogen atom or a hydroxyl-protecting group wherein, R 4 and R 5 are the same or different and is a hydrogen atom or a lower alkyl group)
- R 4 and R 5 are the same as described above, and R 29 and R 3e are the same or different and each have a hydrogen atom, a lower alkyl group, a phenyl group, or R 28 and R 3e together with 5 carbon atoms.
- R 37 is a hydrogen atom or a methoxymethyl group), which is then hydrolyzed under basic conditions to give a compound of the general formula
- R 36 is a lower alkyl group or a benzyl group.
- R 4 and R 5 are the same or different and are a hydrogen atom or a lower alkyl group, and R 35 is a lower alkyl group.
- R 4 , R 5 and R 36 are the same as described above, and then reducing this with a borohydride compound in the presence of a lower alkyl carboxylic acid.
- R 4 and R 5 are the same or different and are a hydrogen atom or a lower alkyl group), or condensed and cyclized in the presence of an acid or diphosphorus pentoxide, or By reacting with the general formula
- R 4 and R 5 are the same as above; R 37 is a hydrogen atom or a methoxymethyl group), which is then hydrolyzed under basic conditions to give a compound of the general formula
- “Lower alkyl” refers to a straight or branched chain alkyl having 1 to 7 carbon atoms, such as methyl, ethyl, ⁇ -propyl, isopropyl, ⁇ -butyl, isobutyl. , Sec-butyl, tert-butyl, n-pentyl, 1-methylbutyl, 2,2-dimethylpropyl, 2,2-dimethylbutyl, 2-methylpentyl, n-hexyl, 2-methylhexyl, etc. Can be.
- those having 1 to 5 carbon atoms are preferable, and those having 1 to 4 carbon atoms, for example, methyl, ethyl, propyl, isopropyl, tert-butyl and the like are particularly preferable.
- Halogen atoms are fluorine, chlorine, bromine and iodine.
- a “lower alkoxy group” is a straight or branched chain alkoxy group having 1 to 7 carbon atoms, such as methoxy, ethoxy, propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, tert — Butoxy and the like. It preferably has 1 to 5 carbon atoms, and particularly preferably has 1 to 4 carbon atoms, for example, methoxy and ethoxy.
- lower alkylamino group is a group in which an amino group is substituted with the above lower alkyl group, for example, methylamino, ethylamino, n-propylamino, isopropylamino, n-butylamino, isobutylamino, tert-butylamino and the like.
- “Lower dialkylamino” refers to an amino group disubstituted with the above lower alkyl And dimethylamino, getylamino, di-n-propylamino, diisopropylamino, di-n-butylamino, ethylmethylamino, propylmethylamino, 1-methylethylmethylamino, butylmethylamino and the like.
- “Lower Arukanoiru group” is Asechiru group, a propionyl group, Puchiriru group, iso butyryl group, valeryl group, isovaleryl group, pivaloyl group, to Kisanoiru group, to Putanoiru group, straight chain C 2 -C 8, such as Okutanoiru group or It is an alkanol group of the branch chain.
- Substituents A "Amino Ashiru group of the acid,” excluding the hydroxyl portion of the carboxyl groups from Amino acids (e.g., H 2 NC H RC OOH) (i.e., H 2 NC H RC O-) a is a natural or unnatural Any of amino acids may be used.
- the “aralkyl group” is a lower alkyl group substituted with an aryl group such as a phenyl group, a 1-naphthyl group or a 2-naphthyl group, and is preferably a phenyl lower alkyl group or a naphthyl lower alkyl group.
- the “ ⁇ -protecting group” is a protecting group used in the ordinary field of amino acid chemistry, and any protecting group may be employed as long as it protects an amino group or an imino group from various reactions.
- a substituted or unsubstituted lower alkanol group such as formyl, acetyl, propionyl, trifluoroacetyl, etc .
- a phthaloyl group an ethoxycarbonyl group, a lower such as tert-butoxydicarbonyl (Boc), tert-amyloxycarbonyl, etc.
- Alkoxycarbonyl group substituted or unsubstituted aralkyloxycarbonyl such as benzyloxycarbonyl (Cbz), p-nitrobenzyloxycarbonyl, etc. Groups; substituted or unsubstituted arylsulfonyl groups such as benzenesulfonyl and tosyl; aralkyl groups such as trityl and benzyl; and methoxymethyl groups. Particularly preferred are an ethoxycarbonyl group, a tert-butoxycarbonyl group, a benzyloxycarbonyl group, and a methoxymethyl group.
- Carboxy protecting group means an ester with a carboxy group, for example, a methyl group, an ethyl group, a tert-butyl group, a benzyl group, a phenacyl group, a trichloroethyl group, a p-nitrobenzyl group, a diphenylmethyl group and the like. Also, any of those used in the ordinary field of amino acid chemistry can be used, and the present invention is not particularly limited to these. Preferred are a methyl group, an ethyl group, a tert-butyl group and a benzyl group.
- N-protecting group elimination reaction refers to a reaction in which an amino or imino group is generated by removing the protecting group from a protected amino or imino group.
- reaction of a carboxy-protecting group refers to a reaction for generating a carboxy group by removing the protecting group from the protected carboxy group.
- the pharmaceutically acceptable salts of the target compound [1] are conventional non-toxic salts, for example, formate, acetate, trifluoroacetate, citrate, maleate, tartrate, methanesulfonate
- Organic acid addition salts such as benzenesulfonate and toluenesulfonate
- inorganic acid addition salts such as hydrochloride, hydrobromide, sulfate and phosphate
- alkali metals such as sodium salt and potassium salt Salts
- alkaline earth metal salts such as calcium salts and magnesium salts
- ammonium salts for example, trimethylamine salts, triethylamine salts, pyridine salts, picoline salts, dicyclohexylamine salts, N, N * dibenzylethylene
- Organic base salts such as diamine; include salts with amino acids such as aspartate, glumate and lysine, but are not limited thereto.
- Particularly preferred are hydrochloride
- Hydrophill protecting group means an ether that forms a hydroxyl group with, for example, a methoxymethyl group, a methoxetoxymethyl group, a benzyloxymethyl group, a tetrahydrovinylyl group, a benzyl group, a trimethylsilyl group, a tert-butyldimethylsilyl group.
- R 3 8 and R 3 8 is ⁇ Ichi or different and each represents a hydrogen atom, a lower alkyl group, a ring-phenylene group or R 3 8 and R 3 9 is carbon together 5-7 formation May be used).
- Compound [4] or a salt thereof is obtained by reacting compound [3] or a reactive derivative thereof at a carboxy group or a salt thereof with compound [2] or a reactive derivative thereof at an amino group or a salt thereof.
- This reaction is a so-called peptide formation reaction, and a known method can be employed.
- P 1 in the compound [3] represents an N-protecting group such as a benzyloquincarbonyl group and a tert-butoxycarbonyl group.
- the reactive derivative means a derivative obtained by activating a group involved in the reaction such as a carboxy group and a amino group by an arbitrary method.
- Suitable salts of the compound [4] may be the salts as exemplified for the compound [1].
- the method for producing compound [2] and analogs thereof will be described later.
- Suitable reactive derivatives at the carboxy group of compound [3] include acid halides, acid anhydrides, activated amides, activated esters and the like. More specifically, acid chlorides; acid azides Substituted phosphoric acids such as dialkylphosphoric acid, phenylphosphoric acid, diphenylphosphoric acid, dibenzylphosphoric acid, halogenated phosphoric acid, etc .; Acid, butyric acid, isobutyric acid, pinocholic acid, pentanoic acid, isopenic acid Mixed anhydrides with acids such as aliphatic carboxylic acids such as acetic acid, 2-ethylbutyric acid, and trichloroacetic acid or aromatic carboxylic acids such as benzoic acid; symmetric acid anhydrides; imidazole; 4-substituted Activated amides with imidazole, dimethylvirazole, triazole or tetrazole; or, for example, cyanomethyl ester, methoxymethyl este
- Suitable salts of the compound [3] and its reactive derivative include, for example, alkali metal salts such as sodium salt and potassium salt, for example, alkaline earth metal salts such as calcium salt and magnesium salt, ammonium salt, for example, trimethylamine salt.
- Base salts such as organic base salts such as triethylamine salt, pyridine salt, picoline salt, dicyclohexylamine salt, N, N'-dibenzylethylenediamine salt; hydrochloride, hydrobromide
- acid addition salts such as inorganic acid addition salts such as sulfates and phosphates.
- Suitable reactive derivatives of the amino group of the compound [2] include a Schiff base imino group formed by the reaction of the compound [2] with a carbonyl compound such as an aldehyde or a ketone, or an enamine type tautomer thereof.
- Suitable salts of the compound [2] and its reactive derivative can be referred to the salts exemplified for the compound [4].
- the reaction is usually carried out with water, for example, alcohols such as methanol and ethanol, acetone, dioxane, acetonitrile, chloroform, methylene chloride, ethylene chloride, tetrahydrofuran, ethyl acetate, N, N-dimethylformamide, pyridine.
- water for example, alcohols such as methanol and ethanol, acetone, dioxane, acetonitrile, chloroform, methylene chloride, ethylene chloride, tetrahydrofuran, ethyl acetate, N, N-dimethylformamide, pyridine.
- the reaction is carried out in such a conventional solvent, but the reaction can be carried out in any other organic solvent that does not adversely influence the reaction.
- These conventional solvents may be used as a mixture with water.
- the reaction also involves alkali metal bicarbonate, tri (lower) alkylamine, pyridyl
- the reaction may be carried out in the presence of an inorganic base or an organic base such as N- (lower) alkylmorpholine, N, N-di (lower) alkylbenzylamine and the like.
- the reaction temperature is not particularly limited, but the reaction is usually performed under cooling or heating.
- Compound [5] or a salt thereof can be produced by subjecting compound [4] or a salt thereof to an elimination reaction of an N-protecting group.
- This elimination reaction is carried out by a conventional method such as hydrolysis, reduction and the like.
- the hydrolysis is preferably performed in the presence of a base or an acid including a Lewis acid.
- Suitable bases include, for example, alkali metals such as sodium and potassium, alkaline earth metals such as magnesium and calcium, hydroxides or carbonates or bicarbonates of these metals, hydrazines such as trimethylamine, triethyl Trialkylamines such as benzoamine, picoline, 1,5-diazabicyclo [4.3.0] nonane 5-ene, 1,4-diazabicyclo [2.2.2] octane, 1,8 diazabicyclo [5.4] [0] inorganic bases and organic bases such as pendecar 7-ene and the like.
- alkali metals such as sodium and potassium
- alkaline earth metals such as magnesium and calcium
- hydroxides or carbonates or bicarbonates of these metals hydrazines such as trimethylamine, triethyl Trialkylamines such as benzoamine, picoline, 1,5-diazabicyclo [4.3.0] nonane 5-ene, 1,4-diazabicyclo [2.2.2
- Suitable acids include, for example, organic acids such as formic acid, acetic acid, propionic acid, trichloroacetic acid, trifluoroacetic acid, 1-hydroxybenzotriazole, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, hydrogen chloride, hydrogen bromide And inorganic acid compounds such as hydrogen fluoride and acid addition salt compounds such as pyridine hydrochloride.
- organic acids such as formic acid, acetic acid, propionic acid, trichloroacetic acid, trifluoroacetic acid, 1-hydroxybenzotriazole
- hydrochloric acid hydrobromic acid
- sulfuric acid hydrogen chloride
- inorganic acid compounds such as hydrogen fluoride and acid addition salt compounds such as pyridine hydrochloride.
- the elimination using a Lewis acid such as boron trifluoride is preferably carried out in the presence of a positive ion scavenger such as anisol or phenol.
- the reaction is usually carried out in water, for example, an alcohol such as methanol or ethanol, a solvent such as methylene chloride, chloroform, tetrachloromethane, tetrahydrofuran, or a mixture thereof, but does not adversely affect the reaction. Any other solvent can be used as long as it is not available. Liquid bases or acids can also be used as solvents.
- the reaction temperature is not particularly limited, and the reaction is usually performed under cooling or heating. Reduction methods applicable to the elimination reaction include chemical reduction and catalytic reduction.
- Suitable reducing agents used in the chemical reduction method are, for example, a combination of a metal such as tin, zinc, iron and an acid such as formic acid, acetic acid, propionic acid and trifluoroacetic acid.
- Suitable catalysts used for catalytic reduction are, for example, platinum catalysts such as platinum black, platinum oxide, etc., palladium catalysts such as palladium black, palladium oxide, palladium-carbon, etc., nickel catalysts such as reduced nickel, Raney nickel, etc., reduced iron , Raney It is a common one such as an iron catalyst such as iron.
- the reduction is usually carried out in conventional solvents or mixtures thereof which do not adversely influence the reaction, such as water, methanol, ethanol, propanol, N, N-dimethylformamide.
- solvents or mixtures thereof which do not adversely influence the reaction
- the acids used for chemical reduction are liquid, they can be used as a solvent.
- Suitable solvents used for the catalytic reduction include the above-mentioned solvents and getyl ether, dioxane, tetrahydrofuran and the like, but any other solvent that does not adversely affect the reaction can be used. Is also possible.
- the reaction temperature for this reduction is not particularly limited, and the reaction is usually performed under cooling to heating.
- the target compound [1] or a salt thereof is formed by condensing the compound [6] or a reactive derivative thereof at the carboxy group or a salt thereof with the compound [5] or a reactive derivative thereof at the amino group or a salt thereof. It can be produced by reacting to form a peptide bond and, if necessary, removing an N-protecting group, a carboxy protecting group, a hydroxyl protecting group, a thiol protecting group and the like.
- This reaction is a peptide formation reaction and should be performed in substantially the same manner as in the first step.
- the reaction method and reaction conditions may be referred to the description of the first step.
- an amino group, an imino group, a carboxy group, a hydroxyl group, a thiol group, etc. which are not involved in the reaction may be protected as necessary. It may be performed before any of the three steps. The elimination of these protecting groups may be performed after any of the first to third steps.
- suitable protecting groups, protection and deprotection methods are known in the art (TW Greene and PGM Wuts, "Protective Groups in Organic Synthesis” 1991, John Wiley & Sons, NY and “Basics of Peptide Synthesis.” And experiment ", 1987, Maruzen, Tokyo).
- Compound [8] or a salt thereof is produced by reacting compound [7] or a reactive derivative thereof at an amino group or a salt thereof with compound [6] or a reactive derivative thereof at a carboxy group or a salt thereof.
- P 2 in compound [7] means a carboxy-protecting group such as a methyl group or a benzyl group.
- reaction method is a peptide formation reaction and can be performed in substantially the same manner as the first step of the above-mentioned production method 1, the reaction method and reaction conditions for this reaction are as follows. See the explanation.
- Compound [9] or a salt thereof can be prepared by subjecting the compound [8] or a salt thereof to elimination reaction of the carboxy protecting group P 2.
- Suitable salts of the compound [9] include salts as exemplified for the compound [3]. See the class.
- This reaction is carried out according to a conventional method such as hydrolysis, reduction and the like.
- the hydrolysis is preferably performed in the presence of a base or an acid.
- Suitable salts include, for example, alkali metals such as sodium and potassium, and hydroxides or carbonates of those metals.
- Suitable acids include, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, hydrogen chloride, hydrogen bromide, hydrogen fluoride and the like.
- the hydrolysis is usually carried out in water, an alcohol such as methanol or ethanol, an inert solvent such as methylene chloride, chloroform, tetrachloromethane or tetrahydrofuran, or a mixture thereof, but the solvent does not adversely affect the reaction. If so, any other solvent can be used. Liquid bases or acids can also be used as solvents.
- the temperature of the hydrolysis is not particularly limited, but the reaction is usually carried out under cooling or heating.
- Reduction methods applicable to the elimination reaction include a chemical reduction method and a catalytic reduction method.
- the reactive derivative or the salt thereof at the carboxy group of the compound [9] that can be used in the next step can be produced not only from the compound [9] but also from the compound [8] or a salt thereof.
- an acid hydrazide derivative of compound (9) is used instead of compound (8) or a salt thereof via compound (9).
- an acid azide derivative which is a reactive derivative at the carboxy group of compound [9] can be produced.
- Suitable salts of the reactive derivative of the compound [9] may be the same as those exemplified for the compound [3]. 3rd step
- the target compound [1] or a salt thereof is subjected to a condensation reaction of the compound [2] or a reactive derivative thereof at the amino group or a salt thereof with the compound [9] or a reactive derivative thereof at the carboxy group or a salt thereof. It can be produced by forming a peptide bond and, if necessary, removing an N-protecting group, a hydroxyl-protecting group, a thiol-protecting group and the like.
- This reaction is a peptide formation reaction and can be carried out in substantially the same manner as the first step of the above-mentioned production method 1. See the explanation.
- an amino group, an imino group, a carboxy group, a hydroxyl group and a thiol group which are not involved in the reaction may be protected as necessary. It may be performed before any of the three steps. The elimination of these protecting groups may be performed after any of the first to third steps.
- the description in the third step of Production Method 1 may be referred to. Manufacturing method A
- Compound [13] can be produced by reacting compound [11] with compound [12] in the presence of a Lewis acid.
- Z 4 is tert- butoxycarbonyl group in the compound [1 1], means an N- protecting group such as benzyl O alkoxycarbonyl group, also R 3 5 in the compound [1 2] represents a lower alkyl group.
- Tin tetrachloride as the Lewis acid used tetrachloride titanium emissions, although boron trifluoride ether complex and the like, preferably carried out at c this reaction in a solvent which is tin tetrachloride, the reaction solvent used Any solvent can be used as long as it is not involved, but aprotic solvents such as dichloromethane, chloroform and toluene are preferably used.
- reaction temperature is below room temperature, 80 ° C to 0 ° C.
- Compound [13] (hydroxyl moiety S configuration) is obtained.
- Compound [14] can be produced by protecting the hydroxyl group of compound [13].
- Z 7 represents a hydroxyl-protecting group
- Z 8 may form a oxazolidin ring or an oxazolidinone ring which may be substituted together with a hydrogen atom or Z 7 .
- compound [13] is converted to acetone, 2,2-dimethoxybutane, Manufactured by reacting toxic propene, cyclohexanone, 1,1-dimethoxycyclohexane, acetaldehyde, 1,1-dimethoxetane, butyraldehyde, benzaldehyde, benzaldehyde dimethyl acetal, etc. with acids including Lewis acids as catalysts can do.
- Suitable acids include, for example, organic acids such as P-toluenesulfonic acid and pyridine p-toluenesulfonic acid salt.
- the reaction is carried out without a solvent or in a solvent, and any solvent may be used as long as it does not participate in the reaction, but dichloromethane, tetrahydrofuran, toluene and the like are preferable.
- the reaction temperature is not particularly limited, it is usually carried out under cooling or heating.
- Z 4 is a lower alkoxycarbonyl group such as ethoxycarbonyl, tert-butoxycarbonyl, or benzyloxycarbonyl;
- Compound [13] which is an aralkyloxycarbonyl group such as nitrobenzenedioxycarbonyl It can be produced by condensed cyclization in the presence of a base.
- Suitable bases include, for example, hydroxides of alkali metal and alkaline earth metal such as sodium hydroxide and potassium hydroxide, and metal hydrides such as sodium hydride and potassium hydride.
- Compound [15] can be produced by oxidative cleavage of the olefin moiety of compound [14].
- oxidative cleavage known methods such as a method using ozone, a method using osmium tetroxide and sodium periodate (“New Experimental Chemistry Lecture 15: Oxidation and Reduction [I-I, 1 and 2]”, 1 9 76 years, Maruzen, the fourth step c that may follow in Tokyo)
- Compound [17] can be produced by a so-called Wittig reaction in which compound [15] and phosphonium salt [16] are reacted in the presence of a base.
- R 4 and R 5 in the compound [16] are the same as described above, X 2 represents a halogen atom, and Ph represents a phenyl group.
- Phosphonium salts [16] can be prepared by the reaction of the corresponding alkyl halides with triphenylphosphine. This reaction may be performed according to a known method ("New Experimental Chemistry Course 14, Synthesis and Reaction of Organic Compounds [I]"", Maruzen, Tokyo, 1977).
- Compound [20] can be produced by reacting compound [11] with compound [19] in the presence of a Lewis acid. Note that R 4 , R s and R 35 in compound [19] are the same as described above. This reaction can be carried out in substantially the same manner as in the first step of the above-mentioned production method A, and thus the reaction method and reaction conditions of this reaction may be referred to the description of the first step of production method A. Step 6
- Compound [17] can be produced by protecting the hydroxyl group of compound [20].
- Z 7 and Z 8 in compound [17] are the same as described above. Since this reaction can be carried out in substantially the same manner as in the second step of the above-mentioned production method A, the reaction method and reaction conditions for this reaction may be referred to the description of the second step of production method A. .
- Compounds [18a] and [18b] can be produced by oxidizing the olefin moiety of compound [17].
- Known oxidation methods such as a method using potassium permanganate, a method using osmium tetroxide and N-methylmorpholine-N-oxide, etc. (“New Experimental Chemistry Course 14, Synthesis and Reaction of Organic Compounds [I] J, 1977, Maruzen, Tokyo).
- the isomers [18a] and [18b] can be separated by operations such as recrystallization and chromatography, and each can be obtained as an isomerically pure compound.
- Manufacturing method B
- Compound [22] can be produced by reacting compound [11] with compound [21] in the presence of a Lewis acid.
- Z 4 in the compound [11] represents an N-protecting group
- R 4 , R 5 and R 35 in the compound [21] are the same as described above
- Z 6 is a trimethylsilyl group, methoxymethyl group.
- the Lewis acid to be used include tin tetrachloride, titanium tetrachloride, boron trifluoride etherate, and the like, preferably boron trifluoride etherate.
- This reaction is carried out in a solvent, and any solvent can be used as long as it does not participate in the reaction.
- an aprotic solvent such as dichloromethane, chloroform and toluene is used.
- the reaction temperature is not higher than room temperature, preferably from 180 ° C to 0 ° C.
- an operation such as graphic separation, an isomerically pure compound [22] (hydroxyl moiety S configuration) can be obtained easily and in high yield.
- Compound [23] can be produced by the arc subjected to elimination reaction of the hydroxyl protecting group Z 6. This deprotection reaction is performed by a known method (TWG Greene and PGM Wuts rprotective Groups in Organic Synthesis J 1991 John Wiley
- Compound [25] can be produced by protecting the hydroxyl group of compound [23].
- Z 7 and Z 8 in compound [25] are the same as described above.
- This reaction can be carried out in substantially the same manner as in the second step of the above-mentioned production method A, and thus the reaction method and reaction conditions of this reaction may be referred to the description of the second step of production method A.
- Compound [24] can be produced by protecting the hydroxyl group of compound [22].
- Z 7 and Z 8 in compound [24] are the same as described above.
- This reaction can be carried out in substantially the same manner as in the second step of the above-mentioned production method A, and thus the reaction method and reaction conditions of this reaction may be referred to the description of the second step of production method A.
- Compound [25] can be produced by subjecting compound [24] to an elimination reaction of hydroxyl protecting group Z 6 .
- This deprotection reaction may be performed according to a known method (TWG Greene and PGM Wuts rprotective Groups in Organic Synthesis J 1991, John Wiley & Sons, NY).
- Compounds [18a] and [18b] can be produced by reducing the carbonyl group of compound [25].
- Examples of the reduction method applicable to this reaction include a chemical reduction method and a catalytic reduction method.
- Suitable reducing agents that are used chemically include, for example, hydride metals such as sodium borohydride, lithium borohydride, zinc borohydride (E), lithium aluminum hydride, for example, lithium, sodium, zinc, etc. Examples include metal, aluminum alkoxide, triisobutylaluminum, diborane and the like.
- a suitable catalyst used for the catalytic reduction refer to the suitable catalyst used for the catalytic reduction in the second step of the production method 1.
- the reduction is usually carried out in a conventional solvent which does not adversely influence the reaction, such as water, methanol, ethanol, propanol, tetrahydrofuran, ether, N, N-dimethylformamide or a mixture thereof.
- a conventional solvent which does not adversely influence the reaction
- the reaction temperature is not particularly limited, and the reaction is usually performed under cooling or heating.
- Isomers [18a] and [18b] can be separated by operations such as recrystallization and chromatography, and each can be obtained as an isomerically pure compound. Manufacturing method C
- Compound [26] converts compound [18] to formaldehyde, paraformaldehyde, acetone, dimethoxymethane, 2,2-dimethoxypropane, 2-methoxypropene, cyclohexanone, 1,1-dimethoxycyclohexane, Acetaldehyde, 1,1-dimethoxetane, butyraldehyde, benzaldehyde, benzaldehyde dimethyl acetal, etc.
- Suitable acids include, for example, inorganic acids such as sulfuric acid, and organic acids such as p-toluenesulfonic acid and pyridine p-toluenesulfonic acid salt.
- Suitable bases include, for example, hydroxides or carbonates or bicarbonates of alkali metal and alkaline earth metal such as sodium hydroxide and carbon dioxide, such as sodium hydride and potassium hydride. And the like.
- This reaction is usually performed in tetrahydrofuran, toluene, The reaction is performed in a solvent that does not affect the reaction such as N, N, N-dimethylformamide.
- the reaction temperature is not particularly limited, but the reaction is not usually performed under cooling or heating.
- Compound [2] can be produced by elimination of N_ protecting group and hydroxyl protecting group of compound [26].
- the N-protecting group and hydroxyl protecting group of compound [26] may be simultaneously eliminated under the same conditions, or may be sequentially eliminated under different conditions.
- elimination is performed sequentially under different conditions, either the N-protecting group or the hydroxyl-protecting group may be eliminated first.
- the method of the elimination reaction may be performed according to a known method (TWG Greene and PGMWuts "Protective Groups in Organic Synthesis", 1991, John Wiley & Sons, NY).
- the compound [26] when Z 4 is a benzyloxycarbonyl group and Z 7 and Z 8 are linked to form an oxazolidine ring, the compound is hydrolyzed under acidic conditions.
- the compound [2] is obtained by opening the oxazolidine ring and then reducing to remove the benzyloxycarbonyl group.
- Compound [22a] can be produced by reacting compound [11a] with compound [21] in the presence of a Lewis acid.
- R 36 in the compound [11a] represents a lower alkyl group or a benzyl group
- R 4 , R 5 , R 35 , and Z 6 in the compound [21] are the same as described above.
- This reaction can be carried out in substantially the same manner as in the first step of the above-mentioned production method B, and thus the reaction method and reaction conditions of this reaction may be referred to the description of the first step of production method B.
- This reaction is a compound
- Compound [27] is obtained by using the carbonyl group of compound [22a] in the presence of an organic acid such as acetic acid or propionic acid, and using a borohydride compound such as sodium borohydride or tetramethylammonium borohydride. It can be manufactured by reduction.
- This reaction proceeds with high stereoselectivity, and is represented by [27] (2S, 4S, 5S) —5-amino-6-cyclohexyl-2,4-hexanediol derivative and its stereoisomerism
- the formation ratio of (2R, 4S, 5S) -5-amino-6-cyclohexyl-2,4-hexanediol derivative is 9: 1 or more.
- [27] can be obtained easily and in high yield as an isomerically pure compound by operations such as recrystallization and chromatography-separation.
- the reaction method and reaction conditions for this reaction may be in accordance with known methods (rjournal of American Chemical Society. 110, 3560-3578, 1988) and rW09213827 J.
- Compound [28] can be produced by condensing and cyclizing compound [27] in the presence of a base.
- Suitable bases include, for example, hydroxides of alkali metal and alkaline earth metal such as sodium hydroxide and hydroxylated hydroxide, and metal hydrides such as sodium hydride and potassium hydride.
- Can be This reaction is usually carried out in a mixed solvent of water and alcohol (for example, methanol, ethanol, etc.), dioxane, etc., when an alkali metal or alkali earth metal hydroxide is used as the base.
- a metal hydride is used as the base, the reaction is performed in a solvent such as tetrahydrofuran or N, N-dimethylformamide which does not affect the reaction.
- the reaction temperature is not particularly limited, but the reaction is usually carried out under cooling to room temperature.
- Compound [2 9] can be produced by the arc subjected to elimination reaction of the hydroxyl protecting group Z 6. This deprotection reaction may be performed according to a known method (TWG Greene and PGM Wuts "Protective Groups in Organic Synthesis J 1991, John Wiley & Sons, NY"). Step 5
- Compound [30] is obtained by converting compound [29] to formaldehyde, paraformaldehyde, acetone, dimethoxymethane, 2,2-dimethoxypropane, 2-methoxypropene, cyclohexanone, 1,1-dimethoxycyclohexane , Acetoaldehyde, 1,1-dimethoxetane, butyraldehyde, benzaldehyde, benzaldehyde dimethyl acetal, etc., and an acid including a Lewis acid as a catalyst.
- Suitable acids include, for example, inorganic acids such as sulfuric acid, and organic acids such as P-toluenesulfonic acid and pyridine p-toluenesulfonic acid salt.
- This reaction is usually carried out in a solvent such as tetrahydrofuran, toluene, dichloromethane, N, N-dimethylformamide which does not affect the reaction.
- the reaction temperature is not particularly limited, but the reaction is usually carried out under cooling or heating. This reaction is accelerated by coexisting lithium bromide and the like.
- Compound [2a] can be produced by subjecting compound [30] to ring opening by hydrolysis using a base.
- Suitable bases include hydroxides of alkaline metals and alkaline earth metals such as sodium hydroxide, hydroxide hydroxide, and potassium hydroxide.
- This reaction is usually carried out in a mixed solvent of water and an alcohol (eg, methanol, ethanol, etc.), dioxane, etc.
- the reaction temperature is usually from room temperature to heating, but preferably at a reflux temperature of the solvent, which has a high reaction rate. is there.
- Compound [22b] can be produced by reacting compound [11a] with compound [21a] in the presence of a Lewis acid.
- R 36 in compound [1 la] means a lower alkyl group or a benzyl group, and MOM in compound [21a] means a methoxymethyl group; R 4 , R 5 , and R 35 Is the same as above.c
- This reaction can be carried out in substantially the same manner as the first step of the above-mentioned production method B. Description Please refer to it.
- a pure compound [22 b] (hydroxyl moiety S configuration) is obtained.
- Compound [27a] reacts the carbonyl group of compound [22 b] in the presence of a lower alkyl carboxylic acid such as acetic acid or propionic acid, for example, with sodium borohydride or tetramethylammonium hydride. It can be produced by reduction using a borohydride compound such as hydride.
- Compound [28a] can be produced by condensing and cyclizing compound [27a] in the presence of a base.
- Suitable bases include, for example, hydroxides of alkali metal and alkaline earth metal such as sodium hydroxide and hydroxide hydride, and metal hydrides such as sodium hydride and potassium hydride.
- This reaction is usually carried out in a mixed solvent of water and alcohol (eg, methanol, ethanol, etc.), dioxane, etc., when using a hydroxide of alkali metal or alkaline earth metal as the base.
- the reaction is performed in a solvent such as tetrahydrofuran or N, N-dimethylformamide which does not affect the reaction.
- the reaction temperature is not particularly limited, but the reaction is usually carried out under cooling to room temperature.
- Compound [31] can be produced by condensing and cyclizing compound [28a] in the presence of a Lewis acid such as diphosphorus pentoxide or boron trifluoride etherate complex. This reaction is usually performed in a solvent such as tetrahydrofuran, toluene, or dichloromethane that does not affect the reaction.
- the reaction temperature is not particularly limited, but the reaction is usually carried out under cooling or heating.
- Compound [32] can be produced by reacting compound [28a] with dimethoxymethane and an acid including Lewis acid as a catalyst.
- Suitable acids include inorganic acids such as sulfuric acid, and organic acids such as p-toluenesulfonic acid and pyridine p-toluenesulfonic acid salt.
- This reaction is usually performed in a solvent such as tetrahydrofuran, toluene, dichloromethane, N, N-dimethylformamide which does not affect the reaction.
- the reaction temperature is not particularly limited, but the reaction is usually carried out under cooling to heating, and preferably heating at a high reaction rate. This reaction is accelerated by the coexistence of lithium bromide and the like.
- Compound [2b] can be produced by ring opening compound [31] or [32] by hydrolysis using a base.
- Suitable bases include hydroxides of alkali metals and alkaline earth metals such as sodium hydroxide, potassium hydroxide and barium hydroxide.
- This reaction is usually carried out in a mixed solvent of water, an alcohol (eg, methanol, ethanol, etc.), dioxane, etc.
- the reaction temperature is usually from room temperature to under heating. is there.
- the compound obtained by the above production method can be isolated and purified by a conventional method such as grinding, recrystallization, column chromatography, reprecipitation and the like.
- the compound [1] of the present invention or a pharmaceutically acceptable salt thereof can be orally administered, parenterally administered, or mixed with an organic or inorganic solid or liquid excipient as an active ingredient. It can be used in the form of a pharmaceutical preparation suitable for external administration.
- Pharmaceutical preparations include capsules, tablets, dragees, granules, solutions, suspensions, emulsions and the like. If desired, these preparations may contain auxiliaries, stabilizers, lubricants or emulsifiers, buffering agents and other commonly used additives.
- the compounds represented by the general formulas [I], [I], [IV], [V], [VI] and [VII] are novel compounds and are used for producing the compound [1].
- the Rf value of thin-layer chromatography was measured using Merck's Pre-Coated TLC Plates SILICA GEL 60 F-254 (thickness: 0.25 mm).
- Preparative thin-layer chromatography was performed using Merck's pre-coated silica gel (Pre-Coated SILI CA GEL) 60 F—254 (thickness: 0.25 to 2 mm).
- Column chromatography was performed using Merck's Kieselgel ( Kieselgel) 60 (70 230 mesh or 230 400 mesh) was used.
- MgS_ ⁇ was dried at 4. After evaporating the solvent under reduced pressure, the residue was purified by silica gel column chromatography (AcOE Elution with 5 vZv) to give the title compound (i. 3 g) as a colorless oil (see Table 1).
- the compound (2.2 g) obtained in Production Example 2 was dissolved in a mixed solution of methanol (2 Om 1) and dichloromethane (40 ml), cooled to 175, and then ozone was passed through the solution. did. After the reaction turned blue (1.5 hours), dry nitrogen was bubbled in to remove excess ozone. The reaction solution was added dropwise to a suspension of zinc powder (1.2 g), acetic acid (1.2 ml), methanol (25 m 1) and water (25 m 1) with a force nebulizer at ⁇ 45, and the temperature was raised to room temperature. Stirred for minutes. And extracted twice with dichloromethane and washed with saturated NaHCO 3 aq. The organic layer was dried over MgSO 4, distilling off the solvent medium under reduced pressure to give the title compound as a colorless oil (2. 3 g) (see Table 1).
- Triphenylphosphine (13.5 g) and isopropyl iodide (8.5 g) were heated and stirred at 180 ° C in an autoclave. After 24 hours, the obtained solid was recrystallized from methanol rougetyl ether to obtain yellow-brown crystals (22 g). A solution of the crystals (7.98 g) in dry tetrahydrofuran (5 Oml) was added. The mixture was cooled to C, and n-butyllithium (a 6M hexane solution) (9.5 ml) was added dropwise. After stirring at 0 ° C.
- the sodium hydride monodispersion (60% in oil) (121 mg) was washed with hexane, suspended in DMF (7 ml), and cooled with ice.
- a DMF (3 ml) solution of the compound (50 Omg) obtained in Production Example 1 was added dropwise, and the mixture was stirred for 30 minutes under ice cooling. Ice—The solution was added to a 0.1 M aqueous solution of citric acid (30 ml) and extracted with ethyl acetate (25 ml ⁇ 2).
- the organic layer was washed with saturated NaHC_ ⁇ 3 solution was washed with saturated brine, dried over MgSO 4, the solvent was distilled off reduced pressure.
- the compound (50 Omg) obtained in Production Example 1 was dissolved in dichloromethane (5 ml), and N, N-diisopropylethylamine (0.315 ml) and benzyloxymethyl chloride (0.252) were dissolved. m 1) was added. After stirring at room temperature for 2.5 hours, N, N-diisopropylethylamine (0.315 ml) and benzyloxymethyl chloride (0.252 ml) were added, and the mixture was further stirred at room temperature for 1 hour. Acetate Echiru (20 m 1) was added to the reaction mixture, 0.
- the title compound (34 Omg) was obtained by concentrating the recrystallized mother liquor obtained in Method A> of Production Example 10 and purifying the residue by silica gel column chromatography (eluted with CHC13) (Table 3). See).
- the title compound (17 Omg) was obtained from the compound (340 mg) obtained in Production Example 12 in the same manner as in Production Example 13 (see Table 4).
- the reaction mixture ice one saturated NaHCO 3 solution (200 ml) Niyu After stirring in addition the make, saturating the organic layer N a HC 0 3 solution (200 m), and a saturated saline (200 ml).
- the organic layer was dried over MgSO 4, distilling off the solvent medium under a reduced pressure, the crude product consisting mainly of the title compound (29. 5 g) as a yellow oil.
- a part (1.3 g) of the crude product was purified by silica gel column chromatography to obtain the title compound (0.68 g) as a colorless oil (see Table 5).
- Tetramethylammonium borohydride 13 g was added to a mixed solution of acetic acid (150 ml) and acetonitrile (150 ml) under ice cooling, and the mixture was stirred under ice cooling for 1 hour.
- the reaction solution was added ice one saturated NaHCO 3 solution (500 ml) Niyutsukuri and extracted with Jikurorome Tan (500 ml).
- the compound (1.22 g) obtained in Production Example 23 was dissolved in a mixed solvent of water (12 ml) and 1,4-dioxane (12 ml), and barium hydroxide octahydrate ( 1 1.3 g) was added and the mixture was heated under reflux for 2 days. After cooling to room temperature, water (15 ml) was added, and the mixture was extracted with dichloromethane (40 ml ⁇ 2). The organic layer was dried over MgSO 4, the solvent was evaporated in reduced pressure to give the title compound (0. 9 0 g) as a red oil (see Table 6).
- the title compound (103 mg) was obtained as a colorless oil from the compound (158 mg) obtained in Production Example 16 according to a method similar to that of Production Example 24 ⁇ Method A> (see Table 7). .
- Triethylamine (10.9 g) and piperidinocarbonyl chloride (Synthetic Communications, 17, 1887-1892, 1987) were added to a dichloromethane solution of L-phenylalanine benzyl ester (39.6 g) under ice-cooling. (16 g) was added successively, and the mixture was stirred at room temperature for 24 hours. Water (250 ml) was added to the reaction solution, the organic layer was separated, and the aqueous layer was extracted with dichloromethane (250 ml). The combined organic layers 0. 1 N hydrochloric acid (250 m 1 X 2), and wash with saturated NaHCO 3 solution (250 m 1), dried over MgSO 4, the solvent was distilled off under reduced pressure. The residue was recrystallized from ethyl acetate-hexane to give the title compound (29.3 g) as white crystals (see Table 8).
- Activated carbon (3 Omg) and trichloromethyl formate (1.06 ml) were added to a solution of (2S) —2-hydroxy-3-phenylpropionic acid benzyl ester (3.0 g) in anhydrous tetrahydrofuran (1 Ornl). The mixture was stirred overnight at room temperature. Add dipyridine (3.47 ml) and triethylamine (4.89 ml) to the reaction mixture. A tan (1 Om 1) solution was added and stirred at room temperature for 30 minutes. The reaction mixture was filtered, the filtrate was concentrated under reduced pressure, acetic acid Echiru a (5 0 m l) was added, 0.
- N-benzyloxycarbonyl-L-one! The title compound (79 Omg) was obtained as a white solid from stidine (522 mg) and the compound (49 Omg) obtained in Production Example 24 in the same manner as in Production Example 33 (Table 1). 0).
- the title compound (1.03 g) was obtained as a white solid from the compound (1.43 g) obtained in Production Example 39 by the same method as in Production Example 24 ⁇ Method A> (see Table 10). ).
- the title compound (0.975 g) was obtained as a white solid from the compound (1.86 g) obtained in Production Example 41 in the same manner as in Production Example 36 (see Table 11). .
- the title compound was obtained from the compound (47 Omg) obtained in Production Example 47 in the same manner as in Production Example 32 (see Table 12).
- the compound (326 mg) obtained in Production Example 34 was dissolved in DMF (5 ml), and the solution was dissolved in 4N HC 1-dioxane solution (0.608 ml) and isopentyl nitrite (.0.0) at ⁇ 30 ° C. 12 OmI) was added. -After stirring at 30 ° C for 1 hour, the mixture was cooled to -70 ° C and neutralized by adding triethylamine. A solution of the compound (200 mg) obtained in Preparation Example 24 (5 mg) in DMF (5 ml) was added at 70 ° C, and the mixture was stirred at 4 ° C overnight, and the solvent was distilled off under reduced pressure.
- Example 1 was prepared from p-piperidinosulfonyl-L-phenylalanine (see Japanese Patent Application Laid-Open No. 3-86870) (182 mg) and the compound (19 Omg) obtained in Production Example 40. By a method similar to that of 3, the title compound (169 mg) was obtained as a white solid (see Table 14).
- Example 14 The compound (30 Omg) obtained in Example 1 was dissolved in a mixed solution of ethanol (0.27 ml) and ethyl acetate (5.13 ml), and a 0.2N HC1-ethyl acetate solution (2 .09 ml) was added dropwise. After stirring at room temperature overnight, the crystals were collected by filtration and dried under reduced pressure to obtain the title compound (16 Omg) as white crystals (see Table 16).
- Example 14 The compound (30 Omg) obtained in Example 1 was dissolved in a mixed solution of ethanol (0.27 ml) and ethyl acetate (5.13 ml), and a 0.2N HC1-ethyl acetate solution (2 .09 ml) was added dropwise. After stirring at room temperature overnight, the crystals were collected by filtration and dried under reduced pressure to obtain the title compound (16 Omg) as white crystals (see Table 16).
- Example 14
- Example 2 The compound (30 Omg) obtained in Example 1 was dissolved in ethyl acetate (3 ml), and a solution of citrate monohydrate (92.7 mg) in ethyl acetate (5 ml) was added dropwise. After stirring at room temperature for 15 minutes, the crystals were collected by filtration and dried under reduced pressure to give the title compound (257 mg) as white crystals (see Table 16).
- Example 2 The compound obtained in Example 1 (30 mg) was dissolved in ethyl acetate (4.5 ml), and L-tartaric acid (66 mg) was dissolved in ethyl acetate (5 ml) and ethanol (0.5 ml). It was dropped. After stirring at room temperature overnight, the crystals were collected by filtration and dried under reduced pressure to give the title compound (25 lmg) as white crystals (see Table 16).
- Example 17 The compound (31 mg) obtained in Example 1 was dissolved in ethyl acetate (7 ml), and a solution of methanesulfonic acid (44 mg) in ethyl acetate (5 ml) and ethanol (0.25 ml) was added dropwise. . After stirring at room temperature for 3 hours, the crystals were collected by filtration and dried under reduced pressure to give the title compound (292 mg) as white crystals (see Table 16).
- Example 17 The compound (31 mg) obtained in Example 1 was dissolved in ethyl acetate (7 ml), and a solution of methanesulfonic acid (44 mg) in ethyl acetate (5 ml) and ethanol (0.25 ml) was added dropwise. . After stirring at room temperature for 3 hours, the crystals were collected by filtration and dried under reduced pressure to give the title compound (292 mg) as white crystals (see Table 16).
- Example 17 Example 17
- Example 2 The compound (778 mg) obtained in Example 1 was dissolved in ethyl acetate (1 Oml), and a solution of maleic acid (132 mg) in ethyl acetate (15.5 ml) and ethanol (1.55 ml) was added dropwise. did. After stirring at room temperature overnight, the crystals were collected by filtration and dried under reduced pressure to obtain the title compound (723 mg) as white crystals (see Table 17).
- the present invention is not limited to these examples, and for example, the compounds shown in Tables 18 to 21 also belong to the present invention.
- Two groups were prepared. One group was incubated at 37 for 1 hour, and the other group was incubated at 4 ° C for 1 hour.
- angiotensin I was quantified by the radioimmunoassay method.
- Plasma renin activity was 37. The amount was calculated by subtracting the amount of angiotensin I in the reaction solution incubated at 4 ° C from the amount of angiotensin I in the reaction solution that was incubated at C.
- the inhibitory activity () was determined by the following equation. Control value-Value in the presence of the compound of the present invention
- Inhibitory activity ; was determined X 1 0 0 Control ⁇ 5 0% inhibitory activity molar concentration of inhibitory activity obtained by direct the counted formula (IC 5.). [Using a renin rear bead kit (Dynabot) for measurement] The results are shown in Table 22.
- a 0.1M quencher was added to an assimilated marmosets (weight: 310-370 g) bred for 1 week on a low-salt diet (containing 110% of normal salt, 110 in normal diet).
- the compound of Example 1 (lOmgZkg) dissolved in an acid was orally administered at a ratio of Z ml Zkg.
- Blood pressure was measured before and after administration by the tai1-cuff method, and the antihypertensive effect was calculated as a percentage of the pre-administration value. The results are shown in Table 23.
- the novel dioxacycloalkane compound represented by the above general formula [1] according to the present invention has a strong inhibitory activity against renin and has a sustained antihypertensive effect even when administered orally. Therefore, the target compound [1] of the present invention can be expected to be used as an antihypertensive agent and a therapeutic agent for heart failure which can be orally administered and have excellent durability.
- the compounds represented by the general formulas [I], [1], [IV], [V], [VI] and [VII] according to the present invention are intermediates for producing the target compound [1] of the present invention. Use as a body.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP93919555A EP0656356A1 (en) | 1992-08-21 | 1993-08-18 | Dioxacycloalkane compound with renin-inhibiting activity |
US08/387,808 US5750696A (en) | 1992-08-21 | 1993-08-19 | Dioxacycloalkane compound having renin-inhibitory activity |
KR1019950700665A KR950702977A (ko) | 1992-08-21 | 1995-02-21 | 레닌-저해 활성을 갖는 디옥사시클로알칸 화합물(dioxacycloalkane compound with renin-inhibiting activity) |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP4/244037 | 1992-08-21 | ||
JP24403792 | 1992-08-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1994004523A1 true WO1994004523A1 (en) | 1994-03-03 |
Family
ID=17112778
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1993/001156 WO1994004523A1 (en) | 1992-08-21 | 1993-08-18 | Dioxacycloalkane compound with renin-inhibiting activity |
Country Status (5)
Country | Link |
---|---|
US (1) | US5750696A (ja) |
EP (1) | EP0656356A1 (ja) |
KR (1) | KR950702977A (ja) |
CA (1) | CA2142883A1 (ja) |
WO (1) | WO1994004523A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009507075A (ja) * | 2005-09-07 | 2009-02-19 | シェーリング−プラウ・リミテッド | エステルオキサゾリジン化合物を調製するためのプロセスおよびそれらのフロルフェニコールへの変換 |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7879840B2 (en) * | 2005-08-25 | 2011-02-01 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
US7718644B2 (en) * | 2004-01-22 | 2010-05-18 | The Trustees Of Columbia University In The City Of New York | Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof |
US8022058B2 (en) | 2000-05-10 | 2011-09-20 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
US6489125B1 (en) * | 2000-05-10 | 2002-12-03 | The Trustees Of Columbia University In The City Of New York | Methods for identifying chemical compounds that inhibit dissociation of FKBP12.6 binding protein from type 2 ryanodine receptor |
US20040229781A1 (en) * | 2000-05-10 | 2004-11-18 | Marks Andrew Robert | Compounds and methods for treating and preventing exercise-induced cardiac arrhythmias |
US7393652B2 (en) * | 2000-05-10 | 2008-07-01 | The Trustees Of Columbia University In The City Of New York | Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2) |
US20060293266A1 (en) * | 2000-05-10 | 2006-12-28 | The Trustees Of Columbia | Phosphodiesterase 4D in the ryanodine receptor complex protects against heart failure |
US20040048780A1 (en) * | 2000-05-10 | 2004-03-11 | The Trustees Of Columbia University In The City Of New York | Method for treating and preventing cardiac arrhythmia |
US7544678B2 (en) * | 2002-11-05 | 2009-06-09 | The Trustees Of Columbia University In The City Of New York | Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) |
WO2004080283A2 (en) | 2003-03-07 | 2004-09-23 | The Trustees Of Columbia University, In The City Of New York | Type 1 ryanodine receptor-based methods |
US8710045B2 (en) * | 2004-01-22 | 2014-04-29 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the ryanodine receptors |
FR2866888B1 (fr) * | 2004-02-26 | 2006-05-05 | Sanofi Synthelabo | Derives de alkylpiperazine- et alkylhomopiperazine- carboxylates, leur preparation et leur application en therapeutique |
US7704990B2 (en) * | 2005-08-25 | 2010-04-27 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS62169753A (ja) * | 1986-01-16 | 1987-07-25 | アボツト ラボラトリ−ズ | ペプチジルアミノジオ−ル |
EP0438233A2 (en) * | 1990-01-18 | 1991-07-24 | Pfizer Inc. | Orally active renin inhibitors |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4853383A (en) * | 1975-03-03 | 1989-08-01 | Merck & Co., Inc. | β-blocking substituted imidazoles |
US4761491A (en) * | 1984-12-24 | 1988-08-02 | The Dow Chemical Company | Preparation of 2-substituted-1,3-dioxacycloalkanes from diols and diunsaturated ethers |
US4680284A (en) * | 1985-01-23 | 1987-07-14 | Abbott Laboratories | Modified phenylalanine peptidylaminodiols |
US4861764A (en) * | 1986-11-17 | 1989-08-29 | Macro Chem. Corp. | Percutaneous absorption enhancers, compositions containing same and method of use |
CN1030415A (zh) * | 1987-02-20 | 1989-01-18 | 山之内制药株式会社 | 饱和的杂环碳酰胺衍生物和它的制备方法 |
US5242903A (en) * | 1989-08-05 | 1993-09-07 | Bayer Aktiengesellschaft | Renin inhibitors |
IE903606A1 (en) * | 1989-10-10 | 1991-04-24 | Glaxo Group Ltd | Chemical compounds |
EP0523248A4 (en) * | 1991-02-05 | 1994-07-13 | Japan Tobacco Inc | Process for producing -g(a)-amino--g(b),-g(d)-diol derivative |
US5401851A (en) * | 1992-06-03 | 1995-03-28 | Eli Lilly And Company | Angiotensin II antagonists |
-
1993
- 1993-08-18 CA CA002142883A patent/CA2142883A1/en not_active Abandoned
- 1993-08-18 EP EP93919555A patent/EP0656356A1/en not_active Withdrawn
- 1993-08-18 WO PCT/JP1993/001156 patent/WO1994004523A1/ja not_active Application Discontinuation
- 1993-08-19 US US08/387,808 patent/US5750696A/en not_active Expired - Fee Related
-
1995
- 1995-02-21 KR KR1019950700665A patent/KR950702977A/ko not_active Application Discontinuation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS62169753A (ja) * | 1986-01-16 | 1987-07-25 | アボツト ラボラトリ−ズ | ペプチジルアミノジオ−ル |
EP0438233A2 (en) * | 1990-01-18 | 1991-07-24 | Pfizer Inc. | Orally active renin inhibitors |
Non-Patent Citations (3)
Title |
---|
Biochem. Pharmacol., 40 (4), p. 765-770, 1990. * |
J. Med. Chem., 35 (19), p. 3526 and p. 3532, 1992. * |
See also references of EP0656356A4 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009507075A (ja) * | 2005-09-07 | 2009-02-19 | シェーリング−プラウ・リミテッド | エステルオキサゾリジン化合物を調製するためのプロセスおよびそれらのフロルフェニコールへの変換 |
Also Published As
Publication number | Publication date |
---|---|
US5750696A (en) | 1998-05-12 |
EP0656356A4 (ja) | 1995-07-05 |
EP0656356A1 (en) | 1995-06-07 |
CA2142883A1 (en) | 1994-03-03 |
KR950702977A (ko) | 1995-08-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR910003348B1 (ko) | 펩티딜아미노 디올 | |
Buehlmayer et al. | Synthesis and biological activity of some transition-state inhibitors of human renin | |
US4977277A (en) | Functionalized peptidyl aminodiols and -triols 4-amino-5-cyclohexyl-3-hydroxy-1,2-oxopentane and derivatives thereof | |
WO1994004523A1 (en) | Dioxacycloalkane compound with renin-inhibiting activity | |
HU204284B (en) | Process for producing peptide derivatives containing oxa- or aza-cyclostatine | |
EP0189203A2 (en) | Peptidylaminodiols | |
KR910002694B1 (ko) | 작용화 펩티딜 아미노디올 및 트리올 | |
US5739157A (en) | Diastereomeric pure trifluoromethyl ketone peptide derivatives as inhibitors of human leukocyte elastase | |
US4725583A (en) | Functionalized peptidylaminoalcohols | |
US4985407A (en) | Dipeptide compounds, processes for their preparation and compositions containing them | |
US4994477A (en) | Heterocyclic renin inhibitors | |
HU199874B (en) | Process for producing amino acid-1,2-diketo derivatives | |
EP0560730B1 (en) | New derivatives of beta-amino acids with anti-thrombotic activity | |
US4837204A (en) | Functionalized peptidyl aminodiols and -triols | |
US4857507A (en) | Angiotensinogen analogs | |
JPH058191B2 (ja) | ||
JPH02290836A (ja) | アミノ酸誘導体 | |
US5238923A (en) | Amino-substituted heterocycles as renin inhibitors | |
WO1994006755A1 (en) | Alcohol derivative having renin-inhibiting activity and use thereof | |
JPH04297491A (ja) | Leu(10)−Val(11)−Ile(12)に似た非ペプチド性の配座的に拘束されたトリペプチドを含むジ及びトリペプチドレニン阻害剤 | |
ES2198778T3 (es) | Derivados de naftaleno. | |
HU203118B (en) | Process for producing renin inhibiting dipeptides and pharmaceutical compositions comprising same | |
JPH09512012A (ja) | グリシンカチオン均等体への有機ハライドの亜鉛介在付加によるN−Boc−L−プロパルギルグリシンの合成 | |
JP2630506B2 (ja) | レニン阻害活性を有するジオキサシクロアルカン化合物 | |
JPH0757759B2 (ja) | フッ素含有レニン阻害剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA JP KR US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2142883 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 08387808 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1993919555 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1993919555 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1993919555 Country of ref document: EP |